Neurocognitive Disorders

This report summarises what Blossom’s database shows about psychedelics in neurocognitive disorders, and, just as importantly, what it does not show. The short version: there is a strong and repeatedly articulated biological rationale, encouraging early safety data in Parkinson’s disease, and an active but early clinical pipeline. There is no completed, controlled trial showing that psychedelics treat dementia, slow neurodegeneration, or restore cognition in a neurodegenerative disease. Both halves of that sentence matter.

A note before the evidence

This page is a research summary, not medical advice, and nothing here is a treatment recommendation. Psychedelics are being studied in these conditions; they are not approved treatments for them, and several carry real risks. If you or someone you care for is affected by a neurocognitive disorder, decisions about treatment belong with a qualified clinician.

One more framing point. Blossom currently tracks 96 papers and 32 clinical trials tagged to this topic, and those counts appear on this page. They are broader than they look: the topic tag is leaky, so many tagged trials study cognition incidentally, for example whether ketamine harms thinking during anaesthesia or ECT, or how to prevent post-operative delirium, rather than testing a psychedelic as a therapy for a neurodegenerative disease. Read the numbers as a measure of database coverage, not as a count of dementia treatments.

What is the biological case for trying psychedelics here?

The rationale is consistent across reviews. Classic psychedelics act mainly on the 5-HT2A receptor, which is itself dysregulated in Alzheimer's disease and important for the health of cortical neurons[1]Curr. Topics Behav. Neurosci. (2021). Activating that system appears to stimulate neuroplasticity, synaptic and network remodelling and neurotrophic signalling, and reviews argue this provides a rationale for investigating psychedelics in Alzheimer’s disease and related dementias[2]Eur. Neuropsychopharmacology (2023).

Several mechanisms recur. Beyond plasticity, reviews point to anti-inflammatory effects, sigma-1 receptor activity and neurotrophic factors such as BDNF as routes by which psychedelics might protect or repair neurons, framing them as prospective therapeutics for neurodegenerative disorders[3]J. Neurochemistry (2021). There is also a distinct, more concrete result at the level of a single target: in rats, restoring prefrontal mGluR2 with psilocybin rescued cognitive flexibility[4]Science Advances (2021). And psychedelics reliably change large-scale brain connectivity, disrupting the default mode network acutely, though a systematic review cautions that it is unclear how central the default mode network is to any therapeutic effect[5]Int. J. Neuropsychopharmacology (2022).

The honest reading of the mechanism literature is that it is a strong hypothesis generator and almost entirely preclinical: mice, rats, cells and review articles. Two cautions apply. First, the same plasticity that might repair circuits is non-specific, and reviews are careful to note that promoting growth is not the same as promoting the right growth. Second, a mechanism that works in a dish or a young rodent brain may behave differently in an old, diseased human brain carrying decades of pathology. A plausible mechanism is a reason to run a trial, not a result from one.

Parkinson's disease: the best-developed evidence

Parkinson's is where the human evidence is furthest along. The flagship study is a 2025 open-label pilot of psilocybin therapy in 12 people with Parkinson’s disease[6]Neuropsychopharmacology (2025), described by its authors as the first data on psilocybin’s effects in any neurodegenerative disease. There were no serious adverse events and no worsening of Parkinson’s symptoms, and participants showed improvements in non-motor symptoms, mood and anxiety, with some cognitive measures improving, sustained to three months.

The result is genuinely encouraging and genuinely limited. It had 12 participants, no placebo group and a short follow-up, and the large effect sizes it reports are exactly the kind that expectancy and the absence of a control arm inflate. It is best read as evidence that psilocybin can be given to a Parkinson’s population without making things worse, and that mood and non-motor symptoms are a sensible first target, not as evidence of efficacy.

Two smaller threads sit alongside it. A 2026 case report described low-dose ibogaine in a single patient with Parkinson's[7]J. Psychedelic Studies (2026), with improvements in motor symptoms and mood but worse sleep; as a report of one person it is hypothesis-generating only, and ibogaine carries serious cardiac risks. Preclinically, the non-hallucinogenic 5-HT2A agonist Ariadne rescued motor deficits in a Parkinson’s mouse model, comparably to L-DOPA[8]ACS Chem. Neurosci. (2022), without acting on dopamine receptors, hinting at a route to neuro-therapeutics that keep the biology and drop the trip.

A separate, older strand is worth knowing about because it predates the current wave. The ayahuasca vine Banisteriopsis caapi reduced motor deficits in a primate (marmoset) model of Parkinson’s disease[9]Phytotherapy Research (2018), and its harmala alkaloids act as MAO inhibitors with antioxidant properties, the kind of profile that has long made it a candidate for parkinsonism. It is preclinical and the vine is not the same thing as a purified psychedelic, but it shows the Parkinson’s interest is not new, only newly rigorous.

Alzheimer's, dementia and mild cognitive impairment

For Alzheimer’s disease and related dementias the evidence is review-and-rationale, with no completed efficacy trial. Reviews lay out the mechanistic case in detail and note that human data so far speak to mood and anxiety in early-stage Alzheimer's[1]Curr. Topics Behav. Neurosci. (2021) rather than to cognition, while a 2023 review concludes there is enough rationale to investigate psychedelics for Alzheimer’s and related dementias[2]Eur. Neuropsychopharmacology (2023).

This is also where ethics deserves equal billing with biology. A dedicated ethics analysis of psychedelic medicine for Alzheimer’s[10]AJOB Neuroscience (2022) works through consent in a condition that erodes the self, the meaning of ego-dissolution in a pathology of memory and identity, the impact on carers, and the risk of exploiting desperate families. For mild cognitive impairment and early Alzheimer’s the work that exists is feasibility-stage, including a study of whether psilocybin changes synaptic density in amnestic mild cognitive impairment, a direct test of the synaptogenesis idea in a pre-dementia population.

Traumatic brain injury and stroke

For acquired brain injury, traumatic brain injury and stroke, the key reference is a 2024 review of molecular mechanisms and therapeutic potential[11]Molecular Psychiatry (2024), which frames the relevant biology, neuroinflammation, oxidative stress and impaired plasticity, and argues that psychedelics’ effects on serotonergic, sigma-1 and neurotrophic signalling support investigation, while stating plainly that research focused on psychedelics for brain injury is limited.

The only human cognition data here are again from healthy volunteers. A single dose of LSD improved some memory and language measures the next day while impairing cognitive flexibility[12]Eur. Neuropsychopharmacology (2022), and a double-blind comparison of LSD and psilocybin measured plasma BDNF alongside other markers[13]Neuropsychopharmacology (2022), useful mechanistic detail but a long way from a treatment for brain injury.

What the cognition data actually says

A page about cognition has to confront the most common myth directly: microdosing does not enhance thinking. A double-blind, placebo-controlled study of psilocybin microdosing found no evidence for enhanced wellbeing, creativity or cognitive function[14]Translational Psychiatry (2022), and a naturalistic study likewise reported that microdosing had no impact on cognitive performance[15]J. Psychol. Clin. Psychiatry (2023). A 2025 systematic review of microdosing side effects even lists transient cognitive impairment among the dose-dependent, mild, short-lived effects[16]Neuropharmacology (2025).

Ketamine needs the same care. It impairs cognition acutely in healthy people, yet in people treated for depression repeated dosing can improve processing speed and working memory independent of the antidepressant response[17]J. Psychiatric Research (2020), with similar gains in late-life treatment-resistant depression[18]Neuropsychopharmacology (2021). The cleanest cautionary note comes from psilocybin therapy for depression, where processing-speed gains did not consistently exceed expected practice effects[19]Prog. Neuro-Psychopharmacol. Biol. Psychiatry (2025): improvement on a cognitive test is not the same as a drug improving cognition.

Two reassuring observational findings round out the picture. Long-term ritual ayahuasca users show preserved global cognition and better memory than less-experienced users[20]Eur. Arch. Psychiatry Clin. Neurosci. (2024), and a prospective cohort of older adults found improvements in wellbeing after guided psychedelic use[21]Am. J. Geriatric Psychiatry (2024), though acute effects were attenuated with age. These speak to safety and tolerability more than to treating disease.

The trial pipeline

The forward signal is the pipeline. Active and recently completed studies tagged to this topic concentrate on Parkinson’s disease (psilocybin and ketamine for depression and non-motor symptoms), with early-phase trials in ALS, mild cognitive impairment and early Alzheimer’s, post-concussion syndrome, and mechanistic imaging of synaptic density. They are mostly small, mostly Phase I or II, and oriented first to safety and mood. It is worth saying again that the tagged trial list also pulls in studies that are not about psychedelic therapy at all, such as ketamine used as an anaesthetic for ECT, prevention of post-operative delirium in older surgical patients, and disorders of consciousness; these inflate the raw count without adding to the dementia-therapy evidence. A meaningful number of registered trials in the genuinely on-topic set are also withdrawn, paused or of unknown status, which is a realistic feature of an early field rather than a footnote to hide.

Reading this honestly

So where does that leave a careful reader? The substance is real: a coherent mechanistic rationale, the first safety data showing a psychedelic can be given to a neurodegenerative population without worsening it, and an active pipeline. The hype is anything implying proven cognitive enhancement, dementia treatment or neuroprotection in humans. Holding both at once, taking the promise seriously while refusing to overstate it, is the honest position, and it is the one this page tries to model.